The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnsons supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA).
Read Article
Dr. Jack Cush reviews the news, journal articles and missed quiz questions.
Read Article
A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.
A
Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.
Read Article
Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of
Read Article
Dr. John Cush @RheumNow( View Tweet )
Dr. John Cush @RheumNow( View Tweet )
Dr. John Cush @RheumNow( View Tweet )
Dr. John Cush @RheumNow( View Tweet )
A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.
Read Article
Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.
Read Article
Dr. John Cush @RheumNow( View Tweet )
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
Read Article
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 results compared to risankizumab (RKB) adults with active psoriatic
Read Article
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and,
Read Article
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
